drugset / Trial / NCT06248606
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Phase 2
Recruiting
30 enrolled
Ryan Gentzler, MD
Mirati Therapeutics Inc. · collabUniversity of Virginia · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Timeline
- Start
- 2024-08-06
- Primary completion
- 2027-02-25
- Completion
- 2028-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | 600 mg | Oral |